| Title: |
Consensus classification of posterior cortical atrophy |
| Authors: |
Crutch, SJ; Schott, JM; Rabinovici, GD; Murray, M; Snowden, JS; van der Flier, WM; Dickerson, BC; Vandenberghe, R; Ahmed, S; Bak, TH; Boeve, BF; Butler, C; Cappa, SF; Ceccaldi, M; de Souza, LC; Dubois, B; Felician, O; Galasko, D; Graff-Radford, J; Graff-Radford, NR; Hof, PR; Krolak-Salmon, P; Lehmann, M; Magnin, E; Mendez, MF; Nestor, PJ; Onyike, CU; Pelak, VS; Pijnenburg, Y; Primativo, S; Rossor, MN; Ryan, NS; Scheltens, P; Shakespeare, TJ; Suárez González, A; Tang-Wai, DF; Yong, KX; Carrillo, M; Fox, NC; Alzheimer's Association ISTAART Atypical Alzheimer's Disease and, . |
| Source: |
Alzheimer's & Dementia (2017) (In press). |
| Publication Year: |
2017 |
| Collection: |
University College London: UCL Discovery |
| Subject Terms: |
Alzheimer's disease; Biomarker; Clinico-radiological syndrome; Pathophysiology; Posterior cortical atrophy |
| Description: |
INTRODUCTION: A classification framework for posterior cortical atrophy (PCA) is proposed to improve the uniformity of definition of the syndrome in a variety of research settings. METHODS: Consensus statements about PCA were developed through a detailed literature review, the formation of an international multidisciplinary working party which convened on four occasions, and a Web-based quantitative survey regarding symptom frequency and the conceptualization of PCA. RESULTS: A three-level classification framework for PCA is described comprising both syndrome- and disease-level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and neuroimaging features and exclusion criteria of the clinico-radiological syndrome. Classification level 2 (PCA-pure, PCA-plus) establishes whether, in addition to the core PCA syndrome, the core features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attributable to AD [PCA-AD], Lewy body disease [PCA-LBD], corticobasal degeneration [PCA-CBD], prion disease [PCA-prion]) provides a more formal determination of the underlying cause of the PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional syndrome-level descriptors is discussed in relation to the challenges of defining stages of syndrome severity and characterizing phenotypic heterogeneity within the PCA spectrum. DISCUSSION: There was strong agreement regarding the definition of the core clinico-radiological syndrome, meaning that the current consensus statement should be regarded as a refinement, development, and extension of previous single-center PCA criteria rather than any wholesale alteration or redescription of the syndrome. The framework and terminology may facilitate the interpretation of research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral interventions, pharmacological trials), and provide a foundation for future collaborative work. |
| Document Type: |
article in journal/newspaper |
| File Description: |
text |
| Language: |
English |
| Relation: |
https://discovery.ucl.ac.uk/id/eprint/1544187/ |
| Availability: |
https://discovery.ucl.ac.uk/id/eprint/1544187/1/1-s2.0-S1552526017300407-main.pdf; https://discovery.ucl.ac.uk/id/eprint/1544187/ |
| Rights: |
open |
| Accession Number: |
edsbas.717400D6 |
| Database: |
BASE |